Related Experiment Video
Updated: May 23, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Antitumor activity of Chidamide in hepatocellular carcinoma cell lines
Haijuan Wang1, Yi Guo, Ming Fu
1State Key Laboratory of Molecular Oncology, Cancer Institute/Hospital, CAMS and PUMC, Beijing, People's Republic of China.
Abstract:
Chidamide, the structural analog of MS-275, is a novel and promising histone deacetylase (HDAC) inhibitor for use in cancer therapy. To investigate its effects on cancer cell growth, MTT assay was performed in 10 human cancer cell lines. The data showed that the IC50 of Chidamide ranged from 1 to 13 µM, which was comparable to that of MS-275 in half of the tested cell lines. Furthermore, the growth curve indicated that cell growth was gradually inhibited with an increase in Chidamide dosage, and the inhibition was reversed after drug removal in two hepatocelluclar carcinoma cell lines, BEL-7402 and HCC-9204. To determine cell cycle and apoptosis, FACS was carried out in the BEL-7402 and HCC-9204 cells treated with Chidamide. A decrease in the cell population at S phase and an increase in the cell population at G1 phase occurred in a dose-dependent manner. In addition, Chidamide induced apoptosis and up-regulated p21 mRNA expression. These results suggest that Chidamide may arrest the cell cycle and inhibit the growth of hepatocellular carcinoma cells through up-regulation of p21. Further studies are required to clarify the antitumor activity of Chidamide in vivo and its mechanism in anticancer therapy.
Insights
Chidamide, a histone deacetylase (HDAC) inhibitor, effectively inhibits cancer cell growth and induces apoptosis. Further research is needed to confirm its antitumor activity in vivo.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Chidamide is a novel histone deacetylase (HDAC) inhibitor with potential in cancer therapy.
- Its efficacy and mechanism of action require thorough investigation.
Purpose of the Study:
- To evaluate the effects of Chidamide on cancer cell growth, cell cycle, and apoptosis.
- To compare Chidamide's efficacy with MS-275 in various cancer cell lines.
Main Methods:
- MTT assay was used to determine the IC50 values and assess growth inhibition in 10 human cancer cell lines.
- Flow cytometry (FACS) was employed to analyze cell cycle distribution and apoptosis in Chidamide-treated hepatocellular carcinoma cells.
- p21 mRNA expression was quantified to understand the molecular mechanisms involved.
Main Results:
- Chidamide exhibited IC50 values ranging from 1 to 13 µM, comparable to MS-275 in several cell lines.
- Dose-dependent inhibition of cell growth was observed, with reversibility upon drug removal in BEL-7402 and HCC-9204 cells.
- Chidamide treatment led to G1 phase arrest, increased apoptosis, and dose-dependent upregulation of p21 mRNA expression.
Conclusions:
- Chidamide demonstrates significant potential as an anticancer agent by arresting the cell cycle and inducing apoptosis in hepatocellular carcinoma cells.
- The observed effects are likely mediated through the upregulation of p21.
- Further in vivo studies are warranted to elucidate Chidamide's complete antitumor activity and therapeutic mechanisms.
